Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2024 Oct;207(3):611-614.
doi: 10.1007/s10549-024-07427-2.

Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice

Manali A Bhave #  1 , Julia C F Quintanilha #  2 , Hanna Tukachinsky  3 , Gerald Li  3 , Takara Scott  3 , Jeffrey S Ross  3   4 , Lincoln Pasquina  3 , Richard S P Huang  3 , Heather McArthur  5 , Mia A Levy  3   6 , Ryon P Graf  3 , Kevin Kalinsky  7
Affiliations
Published Erratum

Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice

Manali A Bhave et al. Breast Cancer Res Treat. 2024 Oct.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Prevalence of ESR1mut detected in tissue and liquid specimens of HR(+)HER2(−) mBC in the first three metastatic lines of therapy. ESR1mut detected in TBx (A) and LBx (B). AI aromatase inhibitors, chemo chemotherapy, CDK4/6i CDK 4/6 inhibitors, ET endocrine therapy, HR hormone receptor, LBx liquid biopsy, mBC metastatic breast cancer, mut mutations, SERD selective estrogen receptor degrader (fulvestrant), TBx tissue biopsy, TF ctDNA tumor fraction, Tx therapy
Fig. 3
Fig. 3
Co-occurrence of ESR1mut and PI3K/AKT pathway alterations detected in tissue specimens of HR(+)HER2(−) mBC in the first three metastatic lines of therapy. loss copy loss, mut mutation, PI3K/AKT alterations include AKT1mut, PIK3CAmut, PTENmut, and PTENloss
Fig. 4
Fig. 4
Clinical outcomes of HR(+)HER2(−) metastatic breast cancer patients receiving 1st-line AI + CDK4/6i by ESR1mut detected by TBx. Kaplan–Meier plots show rwTTD (A), rwPFS (B), and rwOS (C) for ESR1mut (n = 22) vs ESR1wt (n = 551). Swimmer plot shows rwTTD (each bar represents therapy duration on 1st line of therapy) and rwPFS (dots represent progression) for patients with ESR1mut ordered by specific ERS1mut (D). AI aromatase inhibitors, ESR1mut ESR1 mutations, ESR1WT ESR1 wild-type, HR hazard ratio, OS overall survival, PFS progression-free survival, rw real-world, TBx tissue biopsy, TTD time to treatment discontinuation
See this image and copyright information in PMC

Erratum for

Publication types

LinkOut - more resources